Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: A historical perspective

Biopolymers - Peptide Science Section

Volumn 90, Issue 3, 2008, Pages 203-212

  Manning, Maurice ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Oxytocin; Synthesis; Vasopressin

Indexed keywords

AMINES; BIOCHEMISTRY; CHELATION; EMPLOYMENT; HELIUM; INDUSTRIAL ECONOMICS;

AMERICAN CHEMICAL SOCIETY; BULGARIA; ENGLAND; GRADUATE STUDENTS; HISTORICAL PERSPECTIVE; HUNGARY; MCGILL UNIVERSITY; OXYTOCIN; SOLID-PHASE METHODS; SOLID-PHASE SYNTHESIS; STEWART; SYNTHESIS; VASOPRESSIN; VASOPRESSIN RECEPTORS;

SYNTHESIS (CHEMICAL);

ARGIPRESSIN; ARGIPRESSIN AGONIST; DEMOXYTOCIN; HORMONE DERIVATIVE; HORMONE RECEPTOR STIMULATING AGENT; OXYTOCIN; OXYTOCIN AGONIST; OXYTOCIN ANTAGONIST; OXYTOCIN DERIVATIVE; OXYTOCIN[4 THREONINE]; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN AGONIST; VASOPRESSIN ANTAGONIST; VASOPRESSIN DERIVATIVE; VASOPRESSIN V1A RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR AGONIST; VASOPRESSIN V2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT;

ACHIEVEMENT; ARTICLE; AWARDS AND PRIZES; BIOASSAY; CHEMICAL REACTION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG PURIFICATION; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; LIGAND BINDING; MEDICAL RESEARCH; NONHUMAN; ORGANIC CHEMISTRY; PEPTIDE SYNTHESIS; PROCESS OPTIMIZATION; PROTEIN ISOLATION; REACTION ANALYSIS; SOLID PHASE SYNTHESIS; AMINO ACID SEQUENCE; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; HISTORY; UNITED STATES;

AMINO ACID SEQUENCE; ANTIHYPERTENSIVE AGENTS; DRUG DESIGN; HISTORY, 20TH CENTURY; OXYTOCIN; UNITED STATES; VASOPRESSINS;

EID: 46749098420     PISSN: 00063525     EISSN: 10970282     Source Type: Journal    
DOI: 10.1002/bip.20802     Document Type: Article

References (72)

1. du Vigneaud, V.; Ressler, C.; Swan, J. M.; Roberts, C. W.; Katsoyannis, P. G. J Am Chem Soc 1954, 76, 3115-3121.
2. du Vigneaud, V. In Nobel Lectures in Chemistry 1942-1962, Vol. 3; Elsevier: Amsterdam, 1966; pp 446-465.
3. Merrifield, R. B. J Am Chem Soc 1963, 85, 2149-2154.
4. Merrifield, B. In Nobel Lecturers 1981-1990; Malvastrom, B. G., Ed.; World Scientific Publishing Company: Singapore, 1992; pp 149-173.
5. Stang, P. J. J Am Chem Soc 2003, 125, 1-8.
6. Takashima, H.; du Vigneaud, V.; Merrifield, R. B. J Am Chem Soc 1968, 90, 1323-1325.
7. Manning, M. J Am Chem Soc 1968, 90, 1348-1349.
8. Merrifield, R. B. In Life During the Golden Age of Peptide Chemistry; Seeman, J. L., Ed.; American Chemistry Society: Washington, DC, 1993; pp 297.
9. Manning, M.; du Vigneaud, V. J Am Chem Soc 1965, 87, 3978-3982.
10. Manning, M.; du Vigneaud, V. Biochemistry 1965, 4, 1884-1888.
11. Jarvis, D.; Manning, M.; du Vigneaud, V. Biochemistry 1967, 6, 1223-1225.
12. Manning, M. In Peptides 2004; Flegel, M.; Fridkin, M.; Gilon, C.; Slaninova, J., Eds.; Kenes International: Geneva, 2005; pp 101-106.
13. Manning, M.; Wuu, T. C.; Baxter, J. W. M. J Chromatogr 1968, 38, 396-398.
14. Manning, M.; Wuu, T. C.; Baxter, J. W. M.; Sawyer, W. H. Experientia 1968, 24, 659-660.
15. Manning, M.; Bankowski, K.; Sawyer, W. H. In Solid Phase Synthesis 1992; Epton, R., Ed.; Intercept Ltd.: Andover, Hants, England, 1992; pp 191-205.
16. Baxter, J. W. M.; Manning, M.; Sawyer, W. H. Biochemistry 1969, 8, 3592-3597.
17. du Vigneaud, V.; Gish, D. T.; Katsoyannis, P. G. J Am Chem Soc 1954, 76, 4751-4752.
18. Sawyer, W. H.; Manning, M.; Heinicke, E.; Perks, A. M. Gen Comp Endocrinol 1969, 12, 387-390.
19. Sawyer, W. H.; Wuu, T. C.; Baxter, J. W. M.; Manning, M. Endocrinology 1969, 85, 385-388.
20. Baxter, J. W. M.; Wuu, T. C.; Manning, M.; Sawyer, W. H. Experientia 1969, 25, 1127-1128.
21. Manning, M.; Baxter, J. W. M.; Wuu, T. C.; Smart-Abbey, V.; Morton, K.; Coy, E. J.; Sawyer, W. H. J Med Chem 1971, 14, 1143-1144.
22. Manning, M.; Sawyer, W. H. Nature 1970, 227, 715-716.
23. Manning, M.; Coy, E.; Sawyer, W. H. Biochemistry 1970, 9, 3925-3929.
24. Berde, B.; Boissonnas, R. A. In Handbook of Experimental Pharmacology; Berde, B., Ed.; Springer-Verlag: Berlin, 1968; Vol. 23, pp 802-870.
25. Manning, M.; Sawyer, W. H. J Lab Clin Med 1989, 114, 617-632. [Published erratum appears in J Lab Clin Med 1990, 115(4), 530].
26. Manning, M.; Lowbridge, J.; Haldar, J.; Sawyer, W. H. J Med Chem 1976, 19, 376-380.
27. Lowbridge, J.; Manning, M.; Haldar, J.; Sawyer, W. H. J Med Chem 1977, 20, 120-123.
28. Manning, M.; Balaspiri, L.; Acosta, M.; Sawyer, W. H. J Med Chem 1973, 16, 975-978.
29. Sawyer, W. H.; Acosta, M.; Balaspiri, L.; Judd, J.; Manning, M. Endocrinology 1974, 94, 1106-1115.
30. Sawyer, W. H.; Acosta, M.; Manning, M. Endocrinology 1974, 95, 140-149.
31. Manning, M.; Lowbridge, J.; Stier, C. T., Jr.; Haldar, J.; Sawyer, W. H. J Med Chem 1977, 20, 1228-1230.
32. Lowbridge, J.; Manning, M.; Haldar, J.; Sawyer, W. H. J Med Chem 1978, 21, 313-315.
33. Bankowski, K.; Manning, M.; Haldar, J.; Sawyer, W. H. J Med Chem 1978, 21, 850-853.
34. Kruszynski, M.; Lammek, B.; Manning, M.; Seto, J.; Haldar, J.; Sawyer, W. H. J Med Chem 1980, 23, 364-368.
35. Manning, M.; Lammek, B.; Kruszynski, M.; Seto, J.; Sawyer, W. H. J Med Chem 1982, 25, 408-414.
36. Manning, M.; Stoev, S.; Bankowski, K.; Misicka, A.; Lammek, B.; Wo, N. C.; Sawyer, W. H. J Med Chem 1992, 35, 382-388.
37. Lowbridge, J.; Manning, M.; Seto, J.; Haldar, J.; Sawyer, W. H. J Med Chem 1979, 22, 565-569.
38. Sawyer, W. H.; Haldar, J.; Gazis, D.; Seto, J.; Bankowski, K.; Lowbridge, J.; Turan, A.; Manning, M. Endocrinology 1980, 106, 81-91.
39. Bankowski, K.; Manning, M.; Seto, J.; Haldar, J.; Sawyer, W. H. Int J Pept Protein Res 1980, 165 382-391.
40. Manning, M.; Kruszynski, M.; Bankowski, K.; Olma, A.; Lammek, B.; Cheng, L. L.; Klis, W. A.; Seto, J.; Haldar, J.; Sawyer, W. H. J Med Chem 1989, 32, 382-391.
41. Manning, M.; Miteva, K.; Pancheva, S.; Stoev, S.; Wo, N. C.; Chan, W. Y. Int J Pept Protein Res 1995, 46, 244-252.
42. Chan, W. Y.; Wo, N. C.; Cheng, L. L.; Manning, M. J Pharmacol Exp Ther 1996, 277, 999-1003.
43. Manning, M.; Stoev, S.; Cheng, L. L.; Wo, N. C.; Chan, W. Y. J Pept Sci 2001, 7, 449-465.
44. Manning, M.; Cheng, L. L.; Stoev, S.; Wo, N. C.; Chan, W. Y.; Szeto, H. H.; Durroux, T.; Mouillac, B.; Barberis, C. J Pept Sci 2005, 11, 593-608.
45. Sawyer, W. H.; Pang, P. K. T.; Seto, J.; McEnroe, M.; Lammek, B.; Manning, M. Science 1981, 212, 49-51.
46. Manning, M.; Lammek, B.; Kolodziejczyk, A.; Seto, J.; Sawyer, W. H. J Med Chem 1981, 24, 701-706.
47. Manning, M.; Olma, A.; Klis, W. A.; Kolodziejczyk, A. M.; Seto, J.; Sawyer, W. H. J Med Chem 1982, 25, 45-50.
48. Manning, M.; Klis, W. A.; Olma, A.; Seto, J.; Sawyer, W. H. J Med Chem 1982, 25, 414-419.
49. Manning, M.; Nawrocka, E.; Misicka, A.; Olma, A.; Klis, W. A.; Seto, J.; Sawyer, W. H. J Med Chem 1984, 27, 423-429.
50. Manning, M.; Olma, A.; Klis, W. A.; Kolodziejczyk, A. M., Nawrocka, E.; Misicka-Kesik, A.; Seto, J.; Sawyer, W. H. Nature 1984, 308, 652-653.
51. Sawyer, W. H.; Bankowski, K.; Misicka, A.; Nawrocka, N.; Kruszynski, M.; Stoev, S.; Klis, W. A.; Przybylski, J. P.; Manning, M. Peptides 1988, 9, 157-163.
52. Manning, M.; Cheng, L. L.; Stoev, S.; Bankowski, K.; Przybylski, J.; Klis, W. A.; Sawyer, W. H., Wo, N. C.; Chan, W. Y. J Pept Sci 1995, 1, 66-79.
53. Manning, M.; Cheng, L. L.; Stoev, S.; Klis, W. A.; Nawrocka, E.; Olma, A.; Sawyer, W. H.; Wo, N. C.; Chan, W. Y. J Pept Sci 1997, 3, 31-46.
54. Manning, M.; Przybylski, J.; Olma, A.; Klis, W. A.; Kruszynski, M.; Wo, N. C.; Pelton, G. H.; Sawyer, W. H. Nature 1987, 329, 839-840.
55. Manning, M.; Klis, W. A.; Przybylski, J.; Kruszynski, M.; Olma, A.; Wo, N. C.; Pelton, G. H.; Sawyer, W. H. Int J Pept Protein Res 1988, 32, 455-467.
56. Manning, M.; Stoev, S.; Kolodziejczyk, A.; Klis, W. A.; Kruszynski, M.; Misicka, A.; Olma, A.; Wo, N. C.; Sawyer, W. H. J Med Chem 1990, 33, 3079-3086.
57. Jard, S.; Lombard, C.; Seyer, R.; Anumelas, A.; Manning, M.; Sawyer, W. H. J Mol Pharmacol 1987, 32, 369-375.
58. Elands, J.; Barberis, C.; Jard, S.; Lammek, B.; Manning, M.; Sawyer, W. H.; de Klot, E. R. FEBS Lett 1988; 229, 251-255.
59. Elands, J.; Barberis, C.; Jard, S.; Tribollet, E.; Dreifuss, J. J.; Bankowski, K.; Manning, M.; Sawyer, W. H. Eur J Pharmacol 1988, 147, 197-207.
60. Schmidt, A.; Audigier, S.; Barberis, C.; Jard, S.; Manning, A Kolodziejczyk, A. S.; Sawyer, W. H. FEBS Lett 1991, 282, 77-81.
61. Barberis, C.; Balestre, M. N.; Jard, S.; Tribollet, E.; Arsenijevic, Y.; Dreifuss, J. J.; Bankowski, K.; Manning, M.; Chan, W. Y., Schlosser, S. S.; Holsboer, E; Elands, J. Neuroendocrinology 1995, 62, 135-146.
62. Ala, Y.; Morin, D.; Mahe, E.; Cotte, N.; Mouillac, B.; Jard, S.; Barberis, C.; Tribollet, E.; Dreifuss, J. J.; Sawyer, W. H.; Wo, N. C.; Chan, W. Y.; Kolodziejczyk, A. S.; Cheng, L. L.; Manning, M. Eur J Pharmacol 1997, 331, 285-293.
63. Chan, W. Y.; Wo, N. C.; Stoev, S.; Cheng, L. L.; Manning, M. Br J Pharmacol 1998, 125, 803-811.
64. Manning, M.; Stoev, S.; Cheng, L. L.,Wo, N. C.; Chan, W. Y. J Recept Signal Transduct Res 1999, 19, 631-644.
65. Manning, M.; Stoev, S.; Cheng, L. L.; Wo, N. C.; Chan, W. Y. J Pept Sci 1999, 5, 472-490.
66. Chan, W.Y.; Wo, N. C.; Stoev, S.; Cheng, L. L.; Manning, M. Exp Physiol 2000, 85S, 7S-18S.
67. Stoev, S.; Cheng, L. L.; Manning, M.; Wo, N. C.; Szeto, H. H. J Pept Sci 2006, 12, 592-604.
68. Manning, M.; Stoev, S.; Cheng, L. L.; Wo, N. C.; Chan, W. Y.; Szeto, H. H. Int J Pept Res Ther 2007, 13, 7-17.
69. Chini, B.; Chinol, M.; Cassoni, P.; Papi, S.; Reversi, A.; Areces, L.; Marrocco, T.; Paganelli, G.; Manning, M.; Bussolati, G. Br J Cancer 2003, 89, 930-936.
70. Cheng, L. L.; Stoev, S.; Manning, M.; Derick, S.; Pena, A.; Ben Mimoun, M.; Guillon, G. J Med Chem 2004, 47, 2375-2388.
71. Pena, A.; Murat, B.; Trueba, M.; Ventura, A.; Wo, N. C.; Szeto, H. H.; Cheng, L. L.; Stoev, S.; Guillon, G.; Manning, M. J Med Chem 2007, 50, 835-847.
72. Chini, B.; Stoev, S.; Cheng, L. L.; Manning, M. In Peptides 2006; Rolka, K.; Rekowski, P.; Silberring, J., Eds.; Kenes International: Geneva, in press.